A Stable, Highly Concentrated Fluorous Nanoemulsion Formulation for in Vivo Cancer Imaging Via F-MRI

Overview

Journal NMR Biomed

Publisher Wiley

Date 2024 Jan 17

PMID 38230415

Authors

Alexa R Heaton

Lawrence M Lechuga

Montira Tangsangasaksri

Kai D Ludwig

Sean B Fain

Sandro Mecozzi

Affiliations

Soon will be listed here.

Abstract

Magnetic resonance imaging (MRI) is a routine diagnostic modality in oncology that produces excellent imaging resolution and tumor contrast without the use of ionizing radiation. However, improved contrast agents are still needed to further increase detection sensitivity and avoid toxicity/allergic reactions associated with paramagnetic metal contrast agents, which may be seen in a small percentage of the human population. Fluorine-19 (F)-MRI is at the forefront of the developing MRI methodologies due to near-zero background signal, high natural abundance of 100%, and unambiguous signal specificity. In this study, we have developed a colloidal nanoemulsion (NE) formulation that can encapsulate high volumes of the fluorous MRI tracer, perfluoro-[15-crown-5]-ether (PFCE) (35% v/v). These nanoparticles exhibit long-term (at least 100 days) stability and high PFCE loading capacity in formulation with our semifluorinated triblock copolymer, M2F8H18. With sizes of approximately 200 nm, these NEs enable in vivo delivery and passive targeting to tumors. Our diagnostic formulation, M2F8H18/PFCE NE, yielded in vivo F-MR images with a high signal-to-noise ratio up to 100 in a tumor-bearing mouse model at clinically relevant scan times. M2F8H18/PFCE NE circulated stably in the vasculature, accumulated in high concentration of an estimated 4-9 × 10F spins/voxel at the tumor site, and cleared from most organs over the span of 2 weeks. Uptake by the mononuclear phagocyte system to the liver and spleen was also observed, most likely due to particle size. These promising results suggest that M2F8H18/PFCE NE is a favorable F-MR diagnostic tracer for further development in oncological studies and potential clinical translation.

References

Yang Y, Yang H, Hu Y, Watson P, Liu H, Geiger T . Immunocompetent mouse allograft models for development of therapies to target breast cancer metastasis. Oncotarget. 2017; 8(19):30621-30643. PMC: 5458155. DOI: 10.18632/oncotarget.15695. View

Delmas T, Piraux H, Couffin A, Texier I, Vinet F, Poulin P . How to prepare and stabilize very small nanoemulsions. Langmuir. 2011; 27(5):1683-92. DOI: 10.1021/la104221q. View

Ludwig K, Hernando D, Roberts N, van Heeswijk R, Fain S . A chemical shift encoding (CSE) approach for spectral selection in fluorine-19 MRI. Magn Reson Med. 2017; 79(4):2183-2189. PMC: 5811371. DOI: 10.1002/mrm.26874. View

Singh Y, Meher J, Raval K, Khan F, Chaurasia M, Jain N . Nanoemulsion: Concepts, development and applications in drug delivery. J Control Release. 2017; 252:28-49. DOI: 10.1016/j.jconrel.2017.03.008. View

Barres A, Molugu S, Stewart P, Mecozzi S . Droplet Core Intermolecular Interactions and Block Copolymer Composition Heavily Influence Oil-In-Water Nanoemulsion Stability. Langmuir. 2019; 35(39):12765-12772. PMC: 7454039. DOI: 10.1021/acs.langmuir.9b01519. View

Ruiz-Cabello J, Walczak P, Kedziorek D, Chacko V, Schmieder A, Wickline S . In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn Reson Med. 2008; 60(6):1506-11. PMC: 2597664. DOI: 10.1002/mrm.21783. View

Kobayashi H, Watanabe R, Choyke P . Improving conventional enhanced permeability and retention (EPR) effects; what is the appropriate target?. Theranostics. 2014; 4(1):81-9. PMC: 3881228. DOI: 10.7150/thno.7193. View

Wu L, Liu F, Liu S, Xu X, Liu Z, Sun X . Perfluorocarbons-Based F Magnetic Resonance Imaging in Biomedicine. Int J Nanomedicine. 2020; 15:7377-7395. PMC: 7537992. DOI: 10.2147/IJN.S255084. View

Ramalho M, Ramalho J, Burke L, Semelka R . Gadolinium Retention and Toxicity-An Update. Adv Chronic Kidney Dis. 2017; 24(3):138-146. DOI: 10.1053/j.ackd.2017.03.004. View

10.

Ahrens E, Flores R, Xu H, Morel P . In vivo imaging platform for tracking immunotherapeutic cells. Nat Biotechnol. 2005; 23(8):983-7. DOI: 10.1038/nbt1121. View

11.

Longmire M, Choyke P, Kobayashi H . Clearance properties of nano-sized particles and molecules as imaging agents: considerations and caveats. Nanomedicine (Lond). 2008; 3(5):703-17. PMC: 3407669. DOI: 10.2217/17435889.3.5.703. View

12.

Janjic J, Shao P, Zhang S, Yang X, Patel S, Bai M . Perfluorocarbon nanoemulsions with fluorescent, colloidal and magnetic properties. Biomaterials. 2014; 35(18):4958-68. PMC: 4058911. DOI: 10.1016/j.biomaterials.2014.03.006. View

13.

Gupta A, Eral H, Hatton T, Doyle P . Nanoemulsions: formation, properties and applications. Soft Matter. 2016; 12(11):2826-41. DOI: 10.1039/c5sm02958a. View

14.

Ruiz-Cabello J, Barnett B, Bottomley P, Bulte J . Fluorine (19F) MRS and MRI in biomedicine. NMR Biomed. 2010; 24(2):114-29. PMC: 3051284. DOI: 10.1002/nbm.1570. View

15.

Li Y, Pu S, Liu Q, Li R, Zhang J, Wu T . An integrin-based nanoparticle that targets activated hepatic stellate cells and alleviates liver fibrosis. J Control Release. 2019; 303:77-90. DOI: 10.1016/j.jconrel.2019.04.022. View

16.

Rogosnitzky M, Branch S . Gadolinium-based contrast agent toxicity: a review of known and proposed mechanisms. Biometals. 2016; 29(3):365-76. PMC: 4879157. DOI: 10.1007/s10534-016-9931-7. View

17.

Fang J, Nakamura H, Maeda H . The EPR effect: Unique features of tumor blood vessels for drug delivery, factors involved, and limitations and augmentation of the effect. Adv Drug Deliv Rev. 2010; 63(3):136-51. DOI: 10.1016/j.addr.2010.04.009. View

18.

Flogel U, Ding Z, Hardung H, Jander S, Reichmann G, Jacoby C . In vivo monitoring of inflammation after cardiac and cerebral ischemia by fluorine magnetic resonance imaging. Circulation. 2008; 118(2):140-8. PMC: 2735653. DOI: 10.1161/CIRCULATIONAHA.107.737890. View

19.

Constantinides C, Maguire M, Stork L, Swider E, Srinivas M, Carr C . Temporal accumulation and localization of isoflurane in the C57BL/6 mouse and assessment of its potential contamination in F MRI with perfluoro-crown-ether-labeled cardiac progenitor cells at 9.4 Tesla. J Magn Reson Imaging. 2016; 45(6):1659-1667. PMC: 5484368. DOI: 10.1002/jmri.25564. View

20.

Iyer A, Khaled G, Fang J, Maeda H . Exploiting the enhanced permeability and retention effect for tumor targeting. Drug Discov Today. 2006; 11(17-18):812-8. DOI: 10.1016/j.drudis.2006.07.005. View